Belfast-based Fusion Antibodies has secured a repeat project worth more than £85,000 with an established US pharmaceutical client, reinforcing the role of specialist biotechnology partners in supporting therapeutic antibody development. The contract combines antibody production with advanced structural analysis, giving the company another opportunity to demonstrate its expertise to a major pharmaceutical customer.

Announced on 22 October 2026, the project will use transient gene expression (TGE) to produce the client’s lead antibody, followed by cryogenic electron microscopy (CryoEM) to examine its structure. As Insider Media reports, the award follows earlier work for the same client, including a humanisation project announced in August 2025. The new contract is expected to be completed within Fusion Antibodies’ current financial year.

The repeat business highlights how pharmaceutical companies can draw on specialist contract research organisations (CROs) for targeted expertise during early-stage drug development. TGE enables researchers to produce antibody material for evaluation, while CryoEM can provide detailed structural insights. Together, these capabilities support the scientific work needed to assess therapeutic candidates, although the contract itself does not confirm a clinical outcome or guarantee further development.

Established in 2001 as a spin-out from Queen’s University Belfast, Fusion Antibodies provides antibody discovery, engineering, production and optimisation services for therapeutic and diagnostic applications. Its work includes antibody humanisation and the development of technologies intended to support drug discovery. The company’s official contract announcement says the new award supports its strategy of building deeper relationships with larger pharmaceutical companies and commercialising technologies such as its OptiMAL platform and microfluidic cell line development. The company has not stated that those technologies form part of this specific project. Its August 2025 announcement confirms the earlier humanisation project for the same client.

For pharmaceutical businesses, specialist partnerships can provide access to technical capabilities without requiring every stage of antibody development to be conducted in-house. Repeat contracts also give service providers an opportunity to build longer-term customer relationships and demonstrate delivery across successive project stages. Fusion Antibodies’ latest award illustrates this commercial model, with the client remaining unnamed in the company’s announcement.

For the sector, the lesson is direct: repeat pharmaceutical contracts can create opportunities for specialist biotechnology firms to apply advanced antibody-development expertise, strengthen industry partnerships and contribute to the research pipeline behind future medicines.

Source: Insider Media / London Stock Exchange / Investegate